Michael Metzger, Syndax Pharmaceuticals CEO
Syndax's menin inhibitor succeeds in pivotal trial, but investors aren't impressed
Syndax Pharmaceuticals said its experimental menin inhibitor met the primary endpoint in a pivotal trial for certain leukemia patients, and it’s planning a regulatory filing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.